[Paroxetine-induced severe hyponatremic rhabdomyolisis].
M
M
Portilla-Botelho
J
J
Ortega-Carnicer
M L
ML
Gómez-Grande
C
C
Martín-Rodríguez
D002412:Cations / Q000378:metabolism; D003128:Coma / Q000097:blood / Q000139:chemically induced; D003866:Depressive Disorder / Q000188:drug therapy; D003937:Diagnosis, Differential; D004830:Epilepsy, Tonic-Clonic / Q000097:blood / Q000139:chemically induced; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008140:Lorazepam / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D032342:Muscle Cells / Q000378:metabolism; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000097:blood / Q000139:chemically induced*; D012462:Saline Solution, Hypertonic / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D002412:Cations; D008140:Lorazepam; D017374:Paroxetine; D012462:Saline Solution, Hypertonic; D017367:Selective Serotonin Reuptake Inhibitors; C023842:lormetazepam
Rabdomiólisis hiponatrémica grave secundaria a paroxetina.